Tirofiban Helps Preserve Platelets During Kidney Treatment
Author Information
Author(s): Andreas Link, Matthias Girndt, Simina Selejan, Ranja Rbah, Michael Böhm
Primary Institution: Universitätsklinikum des Saarlandes
Hypothesis
Does tirofiban preserve platelet number and function in patients with cardiogenic shock and acute kidney injury requiring continuous renal replacement therapy?
Conclusion
The study shows that using tirofiban alongside unfractionated heparin prevents platelet loss and maintains platelet function in critically ill patients.
Supporting Evidence
- Tirofiban significantly decreased platelet-monocyte aggregates compared to unfractionated heparin alone.
- Patients receiving tirofiban had higher platelet counts after one day compared to those receiving only unfractionated heparin.
- No platelet transfusions were necessary in the tirofiban group during the study.
Takeaway
This study found that a medicine called tirofiban can help keep platelets from getting too low in patients who are very sick and need special kidney treatment.
Methodology
Forty patients were randomly assigned to receive either unfractionated heparin or a combination of unfractionated heparin and tirofiban, with platelet loss as the primary endpoint.
Potential Biases
The open-label design may lead to bias in treatment administration and outcome assessment.
Limitations
The study had a small sample size and was open-label, which may introduce bias.
Participant Demographics
Patients had a median age of 71 years, with a mix of male and female participants.
Statistical Information
P-Value
p<0.001
Confidence Interval
0.46, 1.97
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website